Linked Life Data

Prednisolone (Liquid)

Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3509

Statements in which the resource exists.
SubjectPredicateObjectContext
dailymed-drugs:3509rdf:typehttp://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:3509rdf:typedailymed-instance:drugslld:dailymed
dailymed-drugs:3509rdfs:labelPrednisolone (Liquid)lld:dailymed
dailymed-drugs:3509dailymed-instance:dosageDosage of prednisolone syrup should be individualized according to the severity of the disease and the response of the patient. For infants and children, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight. Hormone therapy is an adjunct to and not a replacement for conventional therapy. Dosage should be decreased or discontinued gradually when the drug has been administered for more than a few days. The severity, prognosis, expected duration of the disease, and the reaction of the patient to medication are primary factors in determining dosage. If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. Blood pressure, body weight, routine laboratory studies, including two-hour postprandial blood glucose and serum potassium, and a chest X-ray should be obtained at regular intervals during prolonged therapy. Upper GI X-rays are desirable in patients with known or suspected peptic ulcer disease. The initial dosage of prednisolone syrup may vary from 5 mg to 60 mg per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, prednisolone syrup should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of prednisolone syrup for a period of time consistent with the patient's condition. If after longterm therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.lld:dailymed
dailymed-drugs:3509dailymed-instance:clinicalP...Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs such as prednisolone are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids such as prednisolone cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.lld:dailymed
dailymed-drugs:3509dailymed-instance:activeIng...dailymed-ingredient:Prednis...lld:dailymed
dailymed-drugs:3509dailymed-instance:supplyPrednisolone Syrup, USP is a cherry flavored red liquid containing 15 mg of Prednisolone in each 5 mL (teaspoonful) and is supplied in 240 mL bottles (NDC 58177-910-05) and 480 mL bottles (58177-910-07). Pharmacist: Dispense with a suitable calibrated measuring device to assure proper measuring of dose. Dispense in tight, light-resistant and child-resistant containers as defined in the USP/NF. Store at controlled room temperature 15��C to 30��C (59��F to 86��F). Do Not Refrigerate. Manufactured byKV Pharmaceutical Co. forETHEX CorporationSt. Louis, MO 63044lld:dailymed
dailymed-drugs:3509dailymed-instance:genericDr...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:3509dailymed-instance:activeMoi...dailymed-ingredient:Prednis...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:waterlld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:citric_...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:edetate...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:sucroselld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:glyceri...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:propyle...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:alcohollld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:flavorslld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:sodium_...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:benzoic...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:FD&C_re...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:FD&C_bl...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:ethyl_m...lld:dailymed
dailymed-drugs:3509dailymed-instance:inactiveI...dailymed-ingredient:ammonia...lld:dailymed
dailymed-drugs:3509dailymed-instance:genericMe...Prednisolonelld:dailymed
dailymed-drugs:3509dailymed-instance:fullNamePrednisolone (Liquid)lld:dailymed
dailymed-drugs:3509dailymed-instance:adverseRe...Fluid and Electrolyte Disturbances: sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, hypertension. Musculoskeletal: muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones. Gastrointestinal: peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, ulcerative esophagitis. Dermatologic: impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, may suppress reactions to skin tests. Neurological: convulsions, increased intracranial pressure with papilledema, (pseudo-tumor cerebri) usually after treatment, vertigo, headache. Endocrine: menstrual irregularities, development of Cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents in diabetics. Ophthalmic: posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos. Metabolic: negative nitrogen balance due to protein catabolismlld:dailymed
dailymed-drugs:3509dailymed-instance:indicatio...Prednisolone syrup is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications prednisolone syrup is indicated for systemic dermatomyositis (polymyositis).lld:dailymed
dailymed-drugs:3509dailymed-instance:represent...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:3509dailymed-instance:routeOfAd...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:3509dailymed-instance:namePrednisolonelld:dailymed
http://www4.wiwiss.fu-berli...dailymed-instance:producesD...dailymed-drugs:3509lld:dailymed